Journal Article

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

Lensing, Anthonie W, Brenner, Benjamin, Prins, Martin H, Segers, Annelise, Verhamme, Peter, Wells, Phil, Berkowitz, Scott D, Schellong, Sebastian, Agnelli, Giancarlo, Decousus, Hervé, Piovella, Franco, Gallus, Alex S, Raskob, Gary E, Cohen, Alexander, Bauersachs, Rupert, Misselwitz, Frank, Bounameaux, Henri, Buller, Harry R, Davidson, Bruce L

2010

Overview

In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism; it may become part of the treatment armamentarium for this common clinical problem. Acute venous thromboembolism (i.e., deep-vein thrombosis [DVT] or pulmonary embolism) is a common disorder with an annual incidence of approximately 1 or 2 cases per 1000 persons in the general population. 1 , 2 Short-term treatment is effective, with the risk of recurrent disease — the major complication — reduced from an estimated 25% to about 3% during the first 6 to 12 months of therapy. 3 The risk of recurrence remains after treatment ends and can reach 5 to 10% during the first year. 4 , 5 Standard treatment for acute venous thromboembolism is limited by the need for parenteral heparin initially, with overlapping . . .

• Publisher: Massachusetts Medical Society,Massachussetts Medical Society
• Subject: Acenocoumarol / Acenocoumarol - adverse effects / Acenocoumarol - therapeutic use / Acute Disease / Administration / Administration, Oral / adverse effects / Aged / antagonists & inhibitors / Anticoagulants / Anticoagulants - adverse effects / Anticoagulants - therapeutic use / Biological and medical sciences / Blood and lymphatic vessels / Bone surgery / Cardiology. Vascular system / Cardiovascular & respiratory systems / chemically induced / Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous / Double-Blind Method / Drug therapy / Enoxaparin / Enoxaparin - adverse effects / Enoxaparin - therapeutic use / Factor Xa / Factor Xa Inhibitors / Female / General aspects / Hemorrhage / Hemorrhage - chemically induced / Human health and pathology / Human health sciences / Humans / Injections / Injections, Subcutaneous / Intention to Treat Analysis / Kaplan-Meier Estimate / Life Sciences / Male / Medical and Health Sciences / Medical sciences / Medicin och hälsovetenskap / Medicine (all) / Middle Aged / Morpholines / Morpholines - adverse effects / Morpholines - therapeutic use / Oral / Pulmonary Embolism / Pulmonary Embolism - drug therapy / Rivaroxaban / Sciences de la santé humaine / Subcutaneous / Systèmes cardiovasculaire & respiratoire / therapeutic use / Thiophenes / Thiophenes - adverse effects / Thiophenes - therapeutic use / Veins & arteries / Venous Thromboembolism / Venous Thromboembolism - drug therapy / Venous Thrombosis / Venous Thrombosis - drug therapy / Vitamin K / Vitamin K - antagonists & inhibitors / Warfarin / Warfarin - adverse effects / Warfarin - therapeutic use